Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
Provided By PR Newswire
Last update: May 14, 2025
American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers
Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers
Read more at prnewswire.com
